Researchers argue that palliative care integration into treatment regimens contribute to improving the quality of life for patients in phase 1 clinical trials.
FORTIS, a phase 3 randomized study, evaluated the effects of dose intensity of the frontline fludarabine/cyclophosphamide/rituximab on progression-free and overall survival in adult patients with CLL.
Using a cohort of women from the POSH Study, researchers sought to determine risk factors for changes in weight among younger, premenopausal women receiving adjuvant chemotherapy for early-stage breast cancer.
View detailed drug regimens for the treatment of brain cancer, including treatments such as temozolomide, carboplatin, and methotrexate.
Researchers conducted a meta-analysis to determine the incidence of adverse events among patients assigned to placebo-receiving groups in randomized clinical trials.